Drug Trial Radar · NCT01720602
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Last checked: Nov 20, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Nov 2012
Primary completion
Mar 2015
Study completion Jan 2020
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Nov 2, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
Conditions
- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer
Interventions
vorinostatDrug
Given PO
anastrozoleDrug
Given PO
letrozoleDrug
Given PO
exemestaneDrug
Given PO
positron emission tomographyProcedure
Correlative studies
F-18 16 alpha-fluoroestradiolRadiation
Correlative studies
fludeoxyglucose F 18Radiation
Correlative studies
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECISTTime frame: 8 weeks
- Response Rate According to RECISTTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.